©2025 Stanford Medicine
Hypofractionated Radiotherapy for Localized Prostate Cancer (With CyberKnife or With IMRT)
Not Recruiting
Trial ID: NCT00855647
Purpose
To demonstrate that a hypo-fractionated course of radiotherapy (ie. an accelerated radiotherapy course where fewer but larger doses of radiotherapy are given) is both safe and effective in the treatment of low-risk localized prostate cancer.
Official Title
Hypofractionated Radiotherapy for Localized Prostate Cancer (With CyberKnife or With IMRT)
Stanford Investigator(s)
Eligibility
Inclusion Criteria:- Eligible patients will have clinical stage T1c through T2b, initial PSA level \<10 and a biopsy Gleason score of 3+3 or 3+4 with fewer than 50% of biopsy cores involved.
* Patients who have had any form of prior curative treatment (surgery, radiotherapy, cryotherapy) will not be eligible. A prior course of hormone therapy of less than 3 months duration will be allowed.
* Adult men will be considered.
* No life expectancy restrictions will apply.
* Performance Status will not be considered.
* No requirements for organ or marrow function will be made
* Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria:- No prior prostate treatment will be allowed.
* The use of other concurrent Investigational Agents will not be allowed.
* No exclusion requirements due to co-morbid disease or incurrent illness.
* No requirements regarding history of allergic reactions.
* Pregnancy or nursing patients is not applicable (ie. patients are male).
Intervention(s):
procedure: Hypo-fractionated Radiotherapy
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Gillian McFarlane
6507212034